RESUMO
In Venezuela post-transfusional hepatitis (PTH) data is unknown. We studied, prospectively, 147 patients who received blood transfusions (1 to 48 different blood components). They were screened for HBsAg (Ortho HBsAg Elisa Test System), anti HBc (Ortho HBc Elisa Test System and CORZYME, Abbott Laboratories) and amino-transferases (Doles), before and after transfusions. Only the last 36 patients were tested for anti HCV (Ortho HCV antibody Elisa Test)R from the beginning. The test were performed at 2, 7, 12 and 24 weeks subsequently in the negative recipients. PTH for type B virus was 3.8% (5/131), and for NANBH 2.7% (3/110). In both groups those recipients who had more transfusions had the greatest incidence of PTH. We conclude that anti HBc and ALT must be done in all blood donors to prevent the occurrence of PTH either B virus or NANBH. We suggest also, to include anti HCV screening in blood donors as a mean to make blood transfusion safer.